PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5: (11) International Publication Number: WO 93/16716 A61K 37/02, C07K 7/06, 7/08 A1 (43) International Publication Date: 2 September 1993 (02.09.93) C07K 7/10, 13/00 (21) International Application Number: PCT/US93/01652 (74) Agent: FENTRESS, Susan, B.; Tilton, Fallon, Lungmus & Chestnut, 100 South Wacker Drive, Chicago, IL 60606 (22) International Filing Date: 22 February 1993 (22.02.93) (US). (30) Priority data: (81) Designated States: CA, JP, European patent (AT, BE, CH, 07/841,656 24 February 1992 (24.02.92) US DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, (71) Applicant: NORTHWESTERN UNIVERSITY [US/US]; 633 Clark Street, Evanston, IL 60208 (US). **Published** With international search report. (72) Inventors: BOUCK, Noel, P.; 611 North Kenilworth Avenue, Oak Park, IL 60302 (US). POLVERINI, Peter, J.; 9300 Ewing Avenue, Evanston, IL 60203 (US). GOOD, Deborah, J.; 3921 North Pine Grove, Chicago, IL 60613 (US). FRAZIER, William, A.; 516 Lee Avenue, St. Louis, MO 63119 (US).

(54) Title: METHOD AND COMPOSITION FOR INHIBITING ANGIOGENESIS

(57) Abstract

A method of inhibiting angiogenesis and preparations for use therein are disclosed. The preparations comprise compounds thereof capable of inhibiting vascularization. The method and preparations are especially applicable to the treatment of solid tumors including skin cancers for controlling tumor neovascularization and thereby arresting tumor enlargement.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania	
AU	Australia	GA	Gabon	MW	Malawi .	
BB	Barbados	GB	United Kingdom	NL	Netherlands	
BE	Belgium	GN	Guinca	NO	Norway	
BF	Burkina Faso	GR	Greece 1	NZ	New Zealand	
BG	Bulgaria	HU	Hungary	PL	Poland Portugal	
BJ	Benin	ΙE	Ireland	PT		
BR	Brazil	ΙT	Italy	RO	Romania	
CA	Canada	JР	Japan	RU	Russian Federation Sudan .	
CF	Central African Republic	KP	Democratic People's Republic	SD		
CG	Congo		of Korea	SE	Sweden	
CH	Switzerland	KR	Republic of Korea	SK	Slovak Republic .	
CI	Côte d'Ivoire	ΚZ	Kazakhstan	SN	Senegal	
CM	Cameroon	. 1.1	Liechtenstein	รบ	Soviet Union	
cs	Czechoslovakia -	LK	Sri Lanka	TD	Chad	
CZ	Czech Republic	ı.u	graphmaku.1	TG	Tago	
DE	Germany	MC	Monaco	.UA	Ukraine	
DK	Denmark	MC	Madagascar	บร	United States of America	
ES	Spain	Ml.	Mali	VN	Vict Nam	
FI	Finland	MN	Mongolia			

CLAIMS

We claim:

- 1. A method of inhibiting angiogenesis in a human patient, comprising administering to the patient a vascularization inhibitor comprising a peptide capable of inhibiting vascularization.
- 2. The method of claim 1 in which the patient is being treated for an internal tumor, and said inhibitor before administration is admixed with a slow release agent and thereafter a portion of the mixture is implanted in or adjacent to the tumor.
- 3. The method of claim 2 in which the tumor being treated is a skin cancer and said inhibitor before administration is admixed with a topical vehicle and thereafter applied to the surface of the skin cancer.
- 4. In the treatment of human patients having growing solid tumors with associated neovas-cularization, the method of retarding tumors growth comprising administering to the site of the patient's tumor a vascularization inhibitor comprising a peptide

capable of inhibiting vascularization, said inhibitor being applied to the tumor in an amount effective for retarding its enlargement.

- 5. A therapeutic product for controlling angiogenesis, comprising implantable pellets composed essentially of a slow release agent in admixture with a vascularization inhibitor comprising a peptide thereof capable of inhibiting vascularization.
- 6. A therapeutic product for controlling angiogenesis, comprising a topical vehicle in admixture with a vascularization inhibitor comprising a peptide capable of inhibiting vascularization.
- 7. A therapeutic product for controlling angiogenesis, comprising a parenteral therapeutic vehicle containing a vascularization comprising a peptide capable of inhibiting vascularization.
- 8. The therapeutic preparations of claims 5, 6 and 7 in which said inhibitor contains a region capable of inhibiting angiogenesis as determined by the rat corneal assay.

- 9. A therapeutic preparation for controlling angiogenesis, comprising a therapeutic vehicle containing a vascularization inhibitor comprising a peptide capable of inhibiting vascularization.
- 10. A composition capable of inhibiting vascularization consisting essentially of amino acids selected from Sequence Id. No. 1.
- 11. A composition capable of inhibiting vascularization consisting essentially of amino acids selected from Sequence Id. No. 2.
- 12. The composition of claim 11 wherein said peptide ranges from amino acid numbers 1-15.
- 13. The composition of claim 11 wherein said peptide ranges from amino acids numbers 11-25.
- 14. A composition capable of inhibiting vascularization which consists essentially of peptides having the amino acid sequences:

X - Gly - Val - Gln - Tyr - Arg - X
(Sequence Id. No. 12) wherein X are amino acids which do
not destroy or interfere with inhibition of
vascularization.

- 15. A composition capable of inhibiting vascularization consisting essentially of amino acids selected from sequence Id. No. 3.
- 16. A composition capable of inhibiting vascularization consisting essentially of amino acids selected from sequence Id. No. 4.
- 17. A composition capable of inhibiting vascularization consisting essentially of amino acids selected from sequence Id. No. 5.
- 18. A composition capable of inhibiting vascularization consisting essentially of amino acids selected from Sequence Id. No. 6 wherein X are amino acids which do not destroy or interfere with inhibition of vascularization.
- 19. A composition capable of inhibiting vascularization consisting essentially of amino acids selected from Sequence Id. No. 7 wherein X are amino acids which do not destroy or interfere with inhibition of vascularization.

- 20. A composition capable of inhibiting vascularization consisting essentially of a peptide mimic off TSP-I gene.
- 21. A composition capable of inhibiting vascularization consisting essentially of a peptide mimic off TSP-II gene.
- 22. The composition of Claims 10-19 wherein said composition is linked to a chemical carrier.

1	CLASSIFICATION OF SUBJECT MATTER C(5) :A61K 37/02; C07K 7/06, 7/08, 7/10, 13/00				
US CL :	514/8, 12, 13, 14, 16				
	o International Patent Classification (IPC) or to both	national classification and IPC			
	.DS SEARCHED ocumentation searched (classification system followed	hy classification symbols)			
	514/8, 12, 13, 14, 16, 21; 530/324, 326, 327, 329, 3	•	•		
0.5.					
Documentati	ion searched other than minimum documentation to the	extent that such documents are included	in the fields searched		
			·		
Electronic d	ata base consulted during the international search (nat	ne of data base and, where practicable,	search terms used)		
	q 9, PIR 34, Swiss-Prot 23 ms: SEQ ID NOS 2, 3, 6, 7				
C. DOC	UMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.		
Y	US, A, 4,585,754 (Meisner et al.) 29	April 1986, see the Abstract.	22		
<u>X</u> Y	US, A, 4,898,732 (Fernandez) 06 Feb	20,21			
Y	45-59 and 64-68, column 2, lines 9-15	1-8,22			
X.E.	US A 5 190 918 (Deutch et al.) 02 h	S, A, 5,190,918 (Deutch et al.) 02 March 1993, column 6, lines 1,4,9,18,19			
<u>X</u> ,E Y	45-60, column 11, lines 8-14.				
X,E	US, A, 5,192,744 (Bouck et al.) (document.	1-22			
			4		
		:			
		•			
X Furti	her documents are listed in the continuation of Box C	. See patent family annex.			
1	ecial categories of cited documents:	"T" later document published after the int date and not in conflict with the applic			
	cument defining the general state of the art which is not considered be part of particular relevance	principle or theory underlying the in-	/ention		
	rlier document published on or after the international filing date ocument which may throw doubts on priority claim(s) or which is	"X" document of particular relevance; if considered novel or cannot be considered when the document is taken alone			
cit	ted to establish the publication date of another citation or other ecial reason (as specified)	"Y" document of particular relevance; the			
.O. qq	ocument referring to an oral disclosure, use, exhibition or other cans	considered to involve an inventive combined with one or more other sud being obvious to a person skilled in t	h documents, such combination		
	ocument published prior to the international filing date but later than e priority date claimed	'&' document member of the same paten	t family		
Date of the	actual completion of the international search	Date of mailing of the international se	arch report		
05 April	1993	1 4 APR 1993	}		
	mailing address of the ISA/US oner of Patents and Trademarks	Authorized officer	Kuna s.		
Box PCT	on, D.C. 20231	JEFFREY E. RUSSEL	7777		
1	No. NOT APPLICABLE	Telephone No. (703) 308-0196			

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No. PCT/US93/01652

	·			
C (Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where appropriate, of the relevant passage	ges Relevant to claim No.		
X Y	N.P. Bouck et al., "Current Communications In Molecular Biology", published 1989 by Cold Spring Harbor Laboratory Press (NY), "Suppressor Control of an Inhibitor of Angiogenesis", pages 179-183, see entire document.			
<u>X</u> Y	The Journal Of Cell Biology, Volume 112, No. 5, issued Mar 1991, C.A. Prater et al., "The Properdin-like Type I Repeats Human Thrombospondin Contain a Cell Attachment Site", pag 1031-1040, see page 1037, Figure 8.	of 22		
Х	The Journal Of Biological Chemistry, Volume 265, No. 11, is 15 April 1990, M.K. Wirtz et al., "In Vivo and in vitro Noncovalent Association of Excised $\alpha 1(I)$ Amino-terminal Propeptides with Mutant $pN\alpha 2(I)$ Collagen Chains in Native Mutant Collagen in a Case of Ehlers-Danlos Syndrome, Type VII", pages 6312-6317, see Figures 4 and 6.			
	•			
		•		
	·			
	·			
		·		
		•		
1				

	,		,	
ť				